Online inquiry

IVTScrip™ mRNA-Anti-CD33, CDP-771(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5565MR)

This product GTTS-WQ5565MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD33 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001082618.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 945
UniProt ID P20138
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD33, CDP-771(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ5565MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11845MR IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MK-7684
GTTS-WQ4219MR IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BIIB029
GTTS-WQ977MR IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-368
GTTS-WQ15566MR IVTScrip™ mRNA-Anti-AXL, UNII-FFX71LCS5T(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA UNII-FFX71LCS5T
GTTS-WQ15543MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA UNII-52G405U1E5
GTTS-WQ7055MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Fab-12 variant Y0317
GTTS-WQ11846MR IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MK-7684
GTTS-WQ4408MR IVTScrip™ mRNA-Anti-TNFRSF9, BMS-663513(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-663513
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW